Bruno G, Merletti F, Bargero G, Melis D, Masi I, Ianni A, Novelli G, Pagano G, Cavallo-Perin P (2008) Changes over time in the prevalence and quality of care of type 2 diabetes in Italy: the CasaleMonferrato surveys, 1988 and 2000. Nutr Metab Cardiovasc Dis 18:39–45
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91:1464–1474
Ballard DJ, Humphrey LL, Melton LJ 3rd, Frohnert PP, Chu PC, O’Fallon WM, Palumbo PJ (1988) Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 37:405–412
Huxley R, Barzi F, Woodward M (2006) Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332:73–78
Lee WL, Cheung AM, Cape D, Zinman B (2000) Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 23:962–968
Norhammar A, Stenestrand U, Lindbäck J et al (2008) Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Heart 94:1565–1570
Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, Spila-Alegiani S, Turco S, Velussi M, Ferrannini E (2007) Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30:1241–1247
Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E (2007) Incidence and risk factors for stroke in type2 diabetic patients: the DAI study. Stroke 38:1154–1160
Krämer HU, Müller H, Stegmaier C, Rothenbacher D, Raum E, Brenner H (2012) Type 2 diabetes mellitus and gender-specific risk for colorectal neoplasia. Eur J Epidemiol. doi:10.1007/s10654-012-9686-6
Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R (2010) Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis 20:683–690
Yamaguchi T, Sugimoto T (2011) Bone metabolism and fracture risk in type 2 diabetes mellitus. Endocr J 58:613–624
Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, Chiasserini V, Marchionni N, Rotella CM, Mannucci E (2008) Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 31:199–203
Mezuk B, Eaton WW, Albrecht S, Golden SH (2008) Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31:2383–2390
Mannucci E, Rotella F, Ricca V, Moretti S, Placidi GF, Rotella CM (2005) Eating disorders in patients with type 1 diabetes: a meta-analysis. J Endocrinol Invest 28:417–419
Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo R, Mannucci E, Peri A, Serio M (2007) Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 30:RC26–RC30
Kahn SE, Haffner SM, Heise MA, ADOPT Study Group et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443
Monami M, Dicembrini I, Antenore A, Mannucci E (2011) Dipeptidyl Peptidase 4 inhibitors and bone fractures. A meta-analysis of randomized clinical trials. Diabetes Care 34:2474–2476
Gough S, Belda-Iniesta C, Poole C, Weber M, Russell-Jones D, Falck-Hansen B, Mannucci E, Tuomilehto J (2011) Insulin therapy in diabetes and cancer risk: current understanding and implications for future study. Adv Ther 28(Suppl 5):1–18
Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916–922
Guppy A, Jamal-Hanjani M, Pickering L (2011) Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 7:727–736
Becker DM, Segal J, Vaidya D et al (2006) Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295:1420–1427
Shen H, Herzog W, Drolet M et al (2009) Aspirin resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am J Cardiol 104(4):606–612 (Epub 2009 Jun 21)
Gum PA, Kottke-Marchant K, Poggio ED et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230–235
Lee PY, Chen WH, Ng W et al (2005) Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118:723–727
Berger JS, Roncaglioni MC, Avanzini F et al (2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295:306–313 (Erratum in: JAMA. 2006;295:2002)
Butalia S, Leung AA, Ghali W et al (2011) Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 10:25
Ridker PM, Cook NR, Lee IM et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304
Berger JS, Bhatt DL, Cannon CP et al (2009) The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 54:1935–1945
Wannamethee SG, Papacosta O, Lawlor DA et al (2012) Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study. Diabetologia 55:80–87
Mehta SS, Silver RJ, Aaronson A et al (2006) Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567–570
De Berardis G, Sacco M, Strippoli GFM et al (2009) Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 339:b4531
Ong G, Davis TM, Davis WA et al (2010) Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting. The Fremantle Diabetes Study. Diabetes Care 33:317–321
American Diabetes Association, American Heart Association, American College of Cardiology Foundation, Pignone M, Alberts MJ, Colwell JA et al (2010). Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 55:2878–2886
ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268:1292–1300